List of Excipients in Branded Drug ALBUMINEX

ALBUMINEX Excipient Strategy, Formulation Opportunities, Patent Risk, and Commercial Outlook

Last updated: August 10, 2026

ALBUMINEX is a plasma-derived human albumin injection available in 5% and 25% concentrations. Its commercial value is driven less by novel excipient technology than by control of albumin purity, viral safety, stabilization, container compatibility, manufacturing scale, and regulatory supply. The principal excipient opportunity is to develop albumin-based formulation platforms for biologics, vaccines, cell therapies, diagnostics, and advanced delivery systems rather than to alter the approved ALBUMINEX drug product.

What is ALBUMINEX and how is it formulated?

ALBUMINEX contains human albumin manufactured from pooled human plasma. The product is supplied as a sterile intravenous solution in 5% and 25% strengths. The approved formulation uses stabilizing excipients and sodium-containing buffer components to maintain albumin structure during processing, storage, and administration [1].

ALBUMINEX formulation profile

Attribute	ALBUMINEX 5%	ALBUMINEX 25%
Active ingredient	Human albumin	Human albumin
Albumin concentration	5 g/100 mL	25 g/100 mL
Route	Intravenous	Intravenous
Product type	Plasma-derived biologic	Plasma-derived biologic
Primary formulation objective	Volume replacement and oncotic support	Oncotic support and fluid mobilization
Preservatives	No antimicrobial preservative	No antimicrobial preservative
Stabilization approach	Sodium-based formulation with albumin stabilizers	Sodium-based formulation with albumin stabilizers
Major regulatory risk	Plasma supply, viral safety, sterility, excipient compatibility	Plasma supply, viral safety, sterility, excipient compatibility

The product label identifies albumin as the active ingredient and specifies excipient and electrolyte content, including sodium and stabilizing components. Exact concentrations should be taken from the applicable package insert because they can vary by presentation and market [1].

Albumin is both a therapeutic protein and a functional excipient. Its high binding capacity, low immunogenicity relative to many foreign proteins, and established intravenous use create opportunities in drug formulation. Those opportunities are separate from the approved ALBUMINEX indications.

What excipients are used in ALBUMINEX?

ALBUMINEX uses stabilizers designed to limit albumin denaturation, aggregation, oxidation, and loss of activity during heat treatment and storage. Human albumin products commonly use caprylate, also called octanoate, and acetyltryptophan or N-acetyl-DL-tryptophan as stabilizing agents [1,2].

Functional role of the excipient system

Excipient or formulation component	Primary function	Commercial relevance
Sodium caprylate or caprylate-related stabilizer	Protects albumin during thermal and storage stress	May affect downstream purification and compatibility
N-acetyl-DL-tryptophan	Stabilizes albumin against conformational damage and oxidation	Can influence impurity profile and analytical release testing
Sodium chloride or sodium-containing buffer	Controls tonicity and ionic strength	Relevant to fluid-load and sodium-exposure claims
Water for injection	Vehicle	Requires sterile, endotoxin-controlled supply

The formulation strategy is conservative. It prioritizes preservation of a well-characterized plasma protein over excipient novelty. This is appropriate for a product used in critically ill patients, where unexpected excipient effects can complicate safety assessment.

Which excipients are most important for reformulation?

Caprylate and acetyltryptophan are the highest-value formulation variables. A reformulation program could seek to:

• Reduce total excipient burden.
• Improve oxidation control.
• Reduce particulate formation.
• Maintain stability during refrigerated and room-temperature excursions.
• Improve compatibility with infusion sets and polyolefin containers.
• Reduce sodium exposure in patients receiving high albumin volumes.
• Preserve viral inactivation and pasteurization performance.
• Support higher-concentration or smaller-volume presentations.

A reformulation cannot be evaluated only by monomer content. It must also measure albumin oxidation, free thiol status, ligand binding, aggregate levels, subvisible particles, pH drift, osmolality, extractables, and infusion-device compatibility.

What commercial opportunities exist for ALBUMINEX excipients?

The strongest opportunities are platform-based. ALBUMINEX itself is a finished drug product, but pharmaceutical-grade human albumin can be commercialized as a functional excipient for other biologics.

Albumin as a biologic excipient

Human serum albumin is used or evaluated as:

• A stabilizer for proteins and peptides.
• A carrier for poorly soluble compounds.
• A surface-blocking agent in diagnostic reagents.
• A cryoprotectant for cells and cell-derived products.
• A component of vaccine and viral-vector formulations.
• A protein supplement in cell culture and cell therapy manufacturing.
• A component of nanoparticle and conjugate systems.
• A stabilizer in ophthalmic and parenteral formulations.

The commercial distinction is important. A company selling albumin as an excipient may need a regulatory package different from a company marketing ALBUMINEX as an intravenous therapeutic. Customers will typically require a Certificate of Analysis, source-plasma controls, viral safety documentation, traceability, animal-origin statements, residual impurity data, and change-control commitments.

Highest-value formulation segments

Segment	Albumin function	Opportunity level	Main barrier
Cell therapy	Protein supplement, cryoprotection, shear protection	High	Donor-derived material and lot consistency
Gene therapy	Stabilizer for viral vectors and delivery systems	High	Vector-specific aggregation and potency effects
Vaccines	Protein or particle stabilizer	Medium-high	Platform-specific regulatory comparability
Monoclonal antibodies	Surface and interface protection	Medium	Competition from recombinant albumin and synthetic excipients
Peptides	Solubility and adsorption control	Medium	Dose and container compatibility
Diagnostics	Blocking and carrier protein	High volume, lower margin	Price competition
Ophthalmics	Protein stabilization and surface protection	Medium	Sterility, viscosity, and ocular tolerance
Cell culture media	Growth-supporting protein	High	Cost and scalable supply

The best near-term opportunity is likely a standardized, low-impurity albumin excipient grade for advanced therapies. Cell and gene therapy developers often need a material with stronger documentation than research-grade albumin but more formulation flexibility than a finished intravenous drug product.

How does plasma-derived albumin compare with recombinant albumin?

Recombinant human serum albumin is the principal strategic substitute. It avoids donor-plasma constraints and can provide tighter control over genetic sequence, impurities, and manufacturing consistency. Plasma-derived albumin retains advantages in clinical familiarity, established regulatory precedent, and broad commercial use.

Factor	Plasma-derived albumin	Recombinant albumin
Source	Human plasma	Recombinant expression system
Supply constraint	Dependent on plasma collection	Dependent on bioreactor capacity
Viral risk	Managed through donor screening and viral clearance	Lower risk of human plasma pathogen transmission
Regulatory familiarity	Extensive for intravenous albumin	Product- and use-specific
Lot variability	Potentially higher	Potentially lower
Cost structure	Plasma procurement and fractionation	Fermentation and purification
Excipient use	Established in some applications	Attractive for animal-origin-free systems
Main commercial advantage	Clinical history and availability	Scalability and supply independence

Recombinant albumin is particularly attractive for cell culture, vaccines, and gene therapy where customers seek animal-origin-free or human-plasma-free manufacturing inputs. Plasma-derived ALBUMINEX has stronger positioning in approved therapeutic use, emergency medicine, and indications where clinicians already recognize the product.

What patent protection covers ALBUMINEX and its excipient strategy?

Publicly available product information identifies ALBUMINEX as a plasma-derived human albumin product rather than a small-molecule drug with a conventional composition-of-matter patent estate. The relevant protection is more likely to involve biologic manufacturing know-how, formulation specifications, purification processes, viral inactivation, container systems, and regulatory exclusivity than a single blocking patent.

Patent categories relevant to ALBUMINEX

Patent category	Relevance
Plasma fractionation	Control of albumin recovery, yield, and purity
Viral inactivation	Pasteurization, solvent-detergent processing, and filtration
Stabilizer combinations	Caprylate, tryptophan derivatives, antioxidants, and buffer systems
Low-aggregate formulations	Control of oligomers and subvisible particles
Container closure	Compatibility with glass, elastomers, and infusion systems
High-concentration albumin	Smaller-volume administration and improved logistics
Recombinant albumin	Alternative supply and excipient-grade production
Albumin conjugates	Drug delivery and half-life extension
Albumin-binding compounds	Long-acting small molecules and peptides

A freedom-to-operate review should separate claims covering albumin as a therapeutic product from claims covering albumin as an excipient. A patent on an albumin-stabilized vaccine, for example, may not affect ALBUMINEX marketing, but it could affect the use of ALBUMINEX-derived albumin in that vaccine.

When does ALBUMINEX lose exclusivity?

ALBUMINEX does not have a conventional small-molecule exclusivity timeline comparable to a new chemical entity. Human albumin is a biologic, and competition depends on manufacturing approval, product comparability, supply, and clinical adoption.

FDA regulatory pathway

A competing human albumin product would generally require a biologics license or an approved biologic pathway. The FDA has separate regulatory expectations for plasma-derived products, including donor eligibility, viral testing, viral clearance, process validation, sterility, potency, identity, purity, and lot release [3].

The practical entry barriers are:

1. Reliable plasma supply.
2. Validated fractionation capacity.
3. Viral inactivation and clearance.
4. Consistent albumin purity and aggregate control.
5. Clinical and analytical comparability.
6. FDA inspection readiness.
7. Commercial distribution to hospitals and wholesalers.

There is no established generic substitution model for ALBUMINEX equivalent to an ANDA-based tablet launch. A competitor would need to establish its own biologic product and secure formulary acceptance.

Orange Book and Purple Book status

The Orange Book is designed primarily for approved drug products with patent and exclusivity listings relevant to generic substitution. ALBUMINEX is a biologic product, so the Purple Book and FDA biologics framework are more relevant than Orange Book patent listings [4].

A biosimilar pathway could theoretically be relevant to a reference human albumin product, but practical development would be complex. The sponsor would need to demonstrate high similarity using analytical characterization and, depending on FDA requirements, clinical or pharmacological evidence. Plasma-derived source differences, impurity profiles, stabilizer content, and manufacturing changes could create comparability questions.

Which companies compete with ALBUMINEX?

The competitive market includes plasma fractionators, specialty biologics manufacturers, and recombinant albumin suppliers.

Competitor or platform	Competitive basis
CSL Behring albumin products	Scale, plasma network, hospital reach
Grifols albumin products	Fractionation capacity and global distribution
Kedrion albumin products	Plasma-derived portfolio and regional presence
Octapharma albumin products	Plasma-derived biologics and international supply
Takeda plasma-derived products	Large plasma infrastructure and global regulatory capabilities
Recombinant albumin suppliers	Animal-origin-free positioning and supply diversification

Product-level competition varies by country. Hospital purchasing decisions often depend on contracted price, supply reliability, concentration, clinical protocols, and distributor availability.

What generic entry risks exist for ALBUMINEX?

The near-term risk is more likely to arise from branded biologic competition and procurement pressure than from a conventional generic launch.

Entry scenarios

Scenario	Timing profile	Commercial effect
Additional plasma-derived albumin supplier	Medium term	Price pressure and hospital tender competition
Recombinant albumin adoption	Medium to long term	Erodes excipient and manufacturing-input demand
Biosimilar-like albumin product	Long term and technically uncertain	Potential substitution if FDA pathway matures
Reformulated high-concentration product	Medium term	Differentiates on fluid management and logistics
Albumin-free biologic formulations	Immediate in selected segments	Reduces demand for albumin as an excipient
Regional shortage or plasma disruption	Variable	Raises value of secure supply and dual sourcing

ALBUMINEX is most exposed where hospitals can switch products based on price and availability. It is less exposed where clinical protocols specify concentration, brand, or supplier qualification.

What formulation patents and manufacturing barriers create commercial value?

The strongest defensible assets are process and formulation packages that solve measurable problems.

High-value technical targets

• Low-aggregate albumin at 25% concentration.
• Reduced oxidation without compromising viral inactivation.
• Low-sodium albumin formulations.
• Longer room-temperature stability.
• Compatibility with closed-system infusion devices.
• Reduced adsorption to tubing and containers.
• Albumin grades optimized for cell and gene therapy.
• Recombinant or plasma-derived albumin with defined impurity limits.
• Lyophilized albumin for reconstitution.
• Albumin nanoparticles with controlled drug loading.
• Albumin-drug conjugates with reproducible release.

A patent filing should focus on defined composition ranges, measurable stability outcomes, manufacturing parameters, and use-specific performance. Broad claims to "albumin plus a stabilizer" are vulnerable where prior art discloses common caprylate or tryptophan-based systems.

What licensing opportunities exist around ALBUMINEX?

The most attractive licensing structures are likely to involve:

1. Albumin excipient supply agreements with cell and gene therapy manufacturers.
2. Regional commercialization rights for human albumin products.
3. Recombinant albumin technology licenses.
4. Albumin nanoparticle and conjugate platforms.
5. Co-development of low-sodium or high-stability albumin formulations.
6. Contract manufacturing using validated plasma fractionation capacity.
7. Dual-source agreements with hospital systems and distributors.

A supplier should seek multiyear agreements with minimum purchase commitments. Customers will value change-control restrictions, lot comparability, reserve inventory, and continuity-of-supply provisions.

How strong is the ALBUMINEX commercial position?

ALBUMINEX has a defensible commercial position based on regulatory experience, manufacturing qualification, and clinical familiarity rather than obvious formulation exclusivity. The strongest assets are operational:

• Access to qualified plasma.
• Validated purification and viral-clearance processes.
• Consistent albumin quality.
• Reliable hospital supply.
• Regulatory approvals across multiple jurisdictions.
• Established distribution.
• Ability to offer both 5% and 25% concentrations.

The main weaknesses are plasma dependence, exposure to tender pricing, limited differentiation among albumin products, and competition from recombinant albumin in excipient applications.

Key Takeaways

• ALBUMINEX is a 5% and 25% plasma-derived human albumin biologic.
• Its excipient system is designed for protein stabilization, not product differentiation through novel excipient chemistry.
• Caprylate and acetyltryptophan-related stabilizers are central formulation variables.
• The largest commercial opportunity is pharmaceutical-grade albumin for cell therapy, gene therapy, vaccines, diagnostics, and biologic formulation.
• Recombinant albumin is the main long-term substitute for plasma-derived albumin in manufacturing applications.
• ALBUMINEX does not follow a conventional generic-drug exclusivity model.
• Competitive entry depends on plasma supply, fractionation, viral safety, comparability, FDA approval, and hospital procurement.
• The most valuable patent opportunities concern low-aggregate formulations, low-sodium products, high-concentration stability, recombinant albumin, and albumin-enabled delivery systems.

FAQs

Is ALBUMINEX an active pharmaceutical ingredient or an excipient?

ALBUMINEX is a finished human albumin drug product. Human albumin can also be used separately as an excipient or manufacturing raw material for other pharmaceutical products.

Can ALBUMINEX be used in cell and gene therapy manufacturing?

Its use may be technically feasible, but the finished drug product is not automatically interchangeable with an excipient-grade albumin raw material. Cell and gene therapy sponsors generally require source, impurity, sterility, viral safety, and change-control documentation specific to the manufacturing use.

Does ALBUMINEX have a 180-day generic exclusivity period?

No conventional ANDA-based 180-day generic exclusivity period applies to ALBUMINEX in the same manner as an approved small-molecule tablet or capsule. Biologic competition follows FDA biologics pathways.

What is the best patent strategy for a new albumin formulation?

The strongest strategy combines composition claims with process, stability, container-compatibility, and use claims. Data should demonstrate reduced aggregation, improved oxidation control, longer storage stability, or superior performance in a defined biologic product.

Is recombinant albumin a direct commercial replacement for ALBUMINEX?

It is a potential substitute in excipient and manufacturing applications, but it is not automatically a therapeutic substitute. Regulatory status, expression system, impurity profile, formulation performance, and clinical indications must be evaluated separately.

References

1. Bio Products Laboratory Limited. (n.d.). ALBUMINEX 5% and ALBUMINEX 25% human albumin injection: Prescribing information. U.S. Food and Drug Administration labeling database.

2. United States Pharmacopeial Convention. (2024). Human albumin. In United States Pharmacopeia and National Formulary.

3. U.S. Food and Drug Administration. (2020). Guidance for industry: Chemistry, manufacturing, and control information for human plasma-derived products.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/